Nose-to-Brain Drug Delivery: A Novel Approach Through Solid Lipid Nanoparticles

Solid Lipid Nanoparticles (SLNs) are now a state-of-the-art substrate allowing delivering medications to CNS, especially when utilizing a nose-to-brain administration method. This thorough analysis summarizes the advancements in SLN composition, emphasizing how they can enhance medication absorption and get over the BBB. The creation of SLNs that can encapsulate both hydrophilic and hydrophobic medicinal compounds has been made easier by developments in fatty membrane choosing, nanoparticle technology, as well as surface activation. By utilizing the sensory and trigeminal neural routes, the inhalation method minimizes broad clearance and side effects thus enabling easy and efficient medication delivery to the cerebral cortex. The physical and chemical factors that affect SLN effectiveness, such as particle size, stability, and releasing kinetics, are examined in this paper. The investigation also highlights the possibility of SLNs to transform therapy approaches for brain cancer, Parkinson's disease, as well as other CNS ailments by discussing recent therapeutic and preclinical trials. Issues with prospective safety, approval procedures, and composition flexibility are included as well. The prospects for non-invasive, targeted brain therapies are presented by the combination of nanostructures and sophisticated administration techniques, which could revolutionize the way that CNS methods for delivering drugs are currently limited. All things considered; it is evident from these observations that SLNs represent a significant breakthrough in contemporary nanotechnology that aims to enhance clinical results.